C WorldWide Group Holding A S boosted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 192.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 113,427 shares of the biopharmaceutical company’s stock after buying an additional 74,676 shares during the period. C WorldWide Group Holding A S’s holdings in Alexion Pharmaceuticals were worth $13,801,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in ALXN. Guardian Life Insurance Co. of America boosted its position in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in Alexion Pharmaceuticals during the first quarter worth about $111,000. Independent Portfolio Consultants Inc. boosted its position in Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 340 shares during the last quarter. Huntington National Bank boosted its position in Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 987 shares during the last quarter. Finally, FUKOKU MUTUAL LIFE INSURANCE Co boosted its position in Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 95.14% of the company’s stock.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at 132.30 on Friday. The stock has a 50 day moving average of $129.17 and a 200 day moving average of $122.91. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $145.42. The company has a market cap of $29.53 billion, a P/E ratio of 57.37 and a beta of 1.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm had revenue of $912 million for the quarter, compared to the consensus estimate of $846.15 million. During the same quarter in the previous year, the firm earned $1.13 EPS. The company’s quarterly revenue was up 21.1% compared to the same quarter last year. On average, analysts expect that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/c-worldwide-group-holding-a-s-has-13-80-million-position-in-alexion-pharmaceuticals-inc-nasdaqalxn/1474448.html.

A number of equities analysts have issued reports on the stock. UBS AG restated a “buy” rating and issued a $140.00 price objective (down previously from $143.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 31st. BMO Capital Markets reiterated an “outperform” rating and set a $158.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, May 1st. SunTrust Banks, Inc. reiterated a “buy” rating and set a $165.00 price target on shares of Alexion Pharmaceuticals in a research report on Friday, July 14th. Leerink Swann reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 23rd. Finally, BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. Five analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $156.89.

In related news, CEO Ludwig Hantson bought 10,000 shares of the stock in a transaction that occurred on Wednesday, June 14th. The stock was bought at an average cost of $116.72 per share, for a total transaction of $1,167,200.00. Following the purchase, the chief executive officer now directly owns 38,725 shares of the company’s stock, valued at $4,519,982. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker bought 1,348,955 shares of the stock in a transaction that occurred on Wednesday, June 14th. The stock was bought at an average price of $116.32 per share, with a total value of $156,910,445.60. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 2,019,734 shares of company stock worth $235,606,846. Insiders own 4.35% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.